Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.

While the trial evaluates safety and efficacy of escalating doses of DMT and CYB004 in healthy volunteers, the novel drug -a deuterated DMT molecule- is being assessed as a potential treatment for Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD.) 

CEO Doug Drysdale said the third …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.